Valuation: Ampliphi Biosciences Corp

Capitalization 72M 68.94M 65.13M 57.43M 102M 6.24B 114M 775M 288M 2.6B 270M 264M 11.01B P/E ratio 2024 *
-2.09x
P/E ratio 2025 * -1.17x
Enterprise value 72M 68.94M 65.13M 57.43M 102M 6.24B 114M 775M 288M 2.6B 270M 264M 11.01B EV / Sales 2024 *
13.1x
EV / Sales 2025 * 13.1x
Free-Float
29.75%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Armata Pharmaceuticals, Inc. Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection Dec. 19 CI
Armata Pharmaceuticals, Inc. Concludes Employment Agreement with Mina Pastagia as Chief Medical Officer Dec. 04 CI
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 Nov. 13 CI
Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia Nov. 12 CI
Armata Pharmaceuticals Announces Principal Financial Officer Changes 24-08-15 CI
Armata Pharmaceuticals, Inc. Announces Appointment of David House as SVP of Finance, Effective August 16 24-08-15 CI
Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02 24-07-30 CI
Armata Pharmaceuticals, Inc. Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled Ap-Pa02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas Aeruginosa Infection 24-07-11 CI
Armata Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 24-05-07 CI
Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q1 Revenue $966,000 24-05-07 MT
Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q4 Revenue $1.5M 24-03-21 MT
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 24-03-21 CI
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 24-03-21 CI
More news
Director TitleAgeSince
Chief Executive Officer 69 2023-07-10
Director of Finance/CFO 41 2024-08-15
Chief Operating Officer - -
Manager TitleAgeSince
Director/Board Member 61 2019-05-08
Director/Board Member 67 2019-10-09
Director/Board Member 65 2020-02-11
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi.($)
+2.07%-3.86%+11.19%+97.78% 119B
+1.57%-6.62%-28.31%+5.62% 72.16B
-0.13%-1.87%+71.66%+145.82% 39.41B
+9.73%+2.37%+35.55%-28.18% 29.44B
+0.98%-1.48%+59.02%+11.49% 24.06B
-1.34%-2.05%+7.04%-31.55% 22.32B
+11.50%+5.56%+385.97%+929.25% 16.09B
-1.17%-2.61%+195.75%+237.06% 14.07B
+0.89%+8.70%-19.81%-31.54% 13.26B
Average +1.49%-0.52%+79.78%+148.42% 38.85B
Weighted average by Cap. +0.56%-2.74%+38.43%+98.34%
See all sector performances

Financials

2024 *2025 *
Net sales 5.5M 5.27M 4.97M 4.39M 7.82M 477M 8.73M 59.24M 21.98M 199M 20.61M 20.2M 841M 5.5M 5.27M 4.97M 4.39M 7.82M 477M 8.73M 59.24M 21.98M 199M 20.61M 20.2M 841M
Net income -34.8M -33.32M -31.48M -27.75M -49.47M -3.02B -55.23M -375M -139M -1.26B -130M -128M -5.32B -68.6M -65.68M -62.05M -54.71M -97.52M -5.95B -109M -739M -274M -2.48B -257M -252M -10.49B
Net Debt - -
More financial data * Estimated data
Logo Ampliphi Biosciences Corp
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. Th Company is engaged in developing and advancing a pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Its two lead candidates addresses both chronic and acute bacterial infections. The Company's first lead candidate focused primarily on chronic bacterial infections is the clinical phage candidate for Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection.
Employees
-
More about the company